CING Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.352

-41.22%

-0.857

-17.63%

-0.513

-52.91%

Estimates Revision

The market is revising No Change the revenue expectations for Cingulate Inc. (CING) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.44%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+244.75%

In Past 3 Month

Stock Price

Go Up

+6.44%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

12.00

High

16.00

Current: 0.000

Low

8.00

Averages

12.00

High

16.00

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$17 -> $16

2025-11-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$17 -> $16

2025-11-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.

Roth Capital

NULL

Buy

upgrade

$10 -> $17

2025-10-14

Reason

Roth Capital

Price Target

$10 -> $17

2025-10-14

upgrade

NULL

Buy

Reason

Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$11 -> $10

2025-08-20

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$11 -> $10

2025-08-20

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $10 from $11 but keeps a Buy rating on the shares. The firm's post-Q2 call with the company's management has further strengthened its conviction for CTx-1301 regulatory acceptance in October and potential approval by mid-2026, the analyst tells investors in a research note. Assuming the NDA receives acceptance with an assigned PDUFA date, Roth expects a slew of launch preparation activities focused on disseminating CTx-1301's value in the crowded ADHD market, the firm added.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$12 -> $11

2025-05-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$12 -> $11

2025-05-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$75 → $60

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$75 → $60

2025-04-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$20

2025-03-06

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$20

2025-03-06

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Cingulate Inc (CING.O) is -1.41, compared to its 5-year average forward P/E of -8.49. For a more detailed relative valuation and DCF analysis to assess Cingulate Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.49

Current PE

-1.41

Overvalued PE

51.94

Undervalued PE

-68.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.37

Current PS

177.54

Overvalued PS

58.88

Undervalued PS

-28.14

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CING News & Events

Events Timeline

No data

News

4.0

2025-11-19Benzinga

Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16

9.0

2025-10-24NASDAQ.COM

INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

9.0

2025-10-23Newsfilter

Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting

People Also Watch

Frequently Asked Questions

What is Cingulate Inc (CING) stock price today?

The current price of CING is 4.63 USD — it has decreased -8.86 % in the last trading day.

What is Cingulate Inc (CING)'s business?

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

What is the price predicton of CING Stock?

What is Cingulate Inc (CING)'s revenue for the last quarter?

Cingulate Inc revenue for the last quarter amounts to -6.00M USD, increased 82.68 % YoY.

What is Cingulate Inc (CING)'s earnings per share (EPS) for the last quarter?

Cingulate Inc. EPS for the last quarter amounts to -4244354.00 USD, increased 9.29 % YoY.

What changes have occurred in the market's expectations for Cingulate Inc (CING)'s fundamentals?

How many employees does Cingulate Inc (CING). have?

Cingulate Inc (CING) has 13 emplpoyees as of January 10 2026.

What is Cingulate Inc (CING) market cap?

Today CING has the market capitalization of 33.26M USD.